Merck KGaA invests Eur250 million in Swiss manufacturing and R&D facility

28 Jan 2020

German company Merck KGaA is investing Euro 250 million in a Swiss biologics facility that bridges manufacturing and research.

The 15,700 square meter Biotech Development Center will be built near Merck’s current manufacturing site in Corsier-sur-Vevey, employing a cross-functional team of around 250 people.

Merck KGaA invests Eur250 million in Swiss manufacturing and R&D facility

“This investment… reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.

Merck said the facility will be equipped with continuous manufacturing and laboratory automation to help accelerate development timelines and will have a flexible-by-design infrastructure that can adapt to evolving technology.

Construction is expected to be completed in 2021 and the Biotech Development Center is anticipated to be fully operational by the end of 2022 following validation by regulatory authorities, Merck said.